行情

SELB

SELB

Selecta生物科学
NASDAQ

实时行情|Nasdaq Last Sale

3.320
+0.180
+5.73%
盘后: 3.320 0 0.00% 16:00 01/17 EST
开盘
3.160
昨收
3.140
最高
3.340
最低
3.100
成交量
72.17万
成交额
--
52周最高
3.500
52周最低
1.280
市值
1.60亿
市盈率(TTM)
-2.0874
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SELB 新闻

  • 华盛早报 | 特朗普弹劾案审讯在即,苹果完成新iPhone研发
  • 华盛通.4小时前
  • 揭秘阿里的帝国式管理
  • 虎嗅APP.4小时前
  • 美参院即将开审特朗普弹劾案 审讯程序仍未决定
  • 中国新闻网.4小时前
  • 二十世纪福克斯电影公司不再姓福克斯
  • 中国新闻网.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

SELB 简况

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
展开

Webull提供Selecta Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。